These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 37947202)

  • 41. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
    Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
    Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.
    Bakouny Z; Flippot R; Braun DA; Lalani AA; Choueiri TK
    Eur Urol Focus; 2020 Jan; 6(1):37-40. PubMed ID: 30827939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
    Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
    Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma.
    Cardenas LM; Deluce JE; Khan S; Gulam O; Maleki Vareki S; Fernandes R; Lalani AA
    Curr Oncol; 2022 Jul; 29(8):5426-5441. PubMed ID: 36005167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
    Calvo E; Porta C; Grünwald V; Escudier B
    Oncologist; 2019 Mar; 24(3):338-348. PubMed ID: 30158285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
    Eisner JR; Beebe KD; Mayhew GM; Shibata Y; Guo Y; Farhangfar C; Farhangfar F; Uronis JM; Mooney J; Milburn MV; Foureau D; White RL; Amin A; Milla ME
    Cancer Res Commun; 2022 Aug; 2(8):894-903. PubMed ID: 36923304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
    Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison D; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Parmar MKB; Larkin J; Meade A
    Contemp Clin Trials; 2021 Sep; 108():106482. PubMed ID: 34538402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant therapy for advanced renal cell carcinoma.
    Meissner MA; McCormick BZ; Karam JA; Wood CG
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma.
    Braun DA; Chakraborty AA
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):827-840. PubMed ID: 37246090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
    Han SC; Yin HQ; Xu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
    Sharma R; Kadife E; Myers M; Kannourakis G; Prithviraj P; Ahmed N
    J Exp Clin Cancer Res; 2021 Jun; 40(1):186. PubMed ID: 34099013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment Landscape of Renal Cell Carcinoma.
    Chen YW; Wang L; Panian J; Dhanji S; Derweesh I; Rose B; Bagrodia A; McKay RR
    Curr Treat Options Oncol; 2023 Dec; 24(12):1889-1916. PubMed ID: 38153686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
    Cetin B; Kosar A
    Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.